Hypothesis-driven diligence, buy-side and sell-side, that translates into a clear investment recommendation, calibrated to each stage of the deal.
Most commercial diligence is built to inform. Ours is built to decide. Every workstream we run ties back to a specific investment committee question, a specific valuation input, or a specific negotiating point, not a generic market overview that gets skimmed and shelved.
We combine primary research with physicians, payers, and KOLs, rigorous epidemiology and forecasting, and hands-on transaction experience to pressure-test the assumptions that matter most to your deal, whether you're evaluating an acquisition, an in-licensing opportunity, or your own asset ahead of a process.
Every engagement moves through the same disciplined sequence, whether it runs over three weeks or twelve.
Align on the investment committee's key questions and decision criteria up front.
Build a defensible view of market size, growth, and competitive intensity.
Validate real-world dynamics directly with clinical and payer stakeholders.
Model key drivers to estimate risk-adjusted commercial potential.
Translate insight into a clear recommendation, including risks and key assumptions.
Tell us about your asset, target, or strategic challenge. We'll follow up within one business day.
Start a Conversation →